The Therapeutic Landscape in Chronic Cough
- PMID: 38127133
- PMCID: PMC10896934
- DOI: 10.1007/s00408-023-00666-y
The Therapeutic Landscape in Chronic Cough
Abstract
In recent years, there has been a substantial increase in the development of antitussive therapies and the first new therapy, gefapixant has been licenced in Europe. This review describes current unlicenced treatments for chronic cough and details treatments currently in development for refractory chronic cough and cough in idiopathic pulmonary fibrosis, as well as compounds previously explored.
Keywords: Antitussives; Idiopathic pulmonary fibrosis; P2X3 antagonists; Refractory chronic cough.
© 2023. The Author(s).
Conflict of interest statement
JAS has received consultancy fees from Axalbion, Algernon, AstraZeneca, Bayer, Bellus Health, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Merck, Nocion Therapeutics, Shionogi, and Trevi Therapeutics. The VitaloJAK algorithm has been licenced by Manchester University Foundation Trust (MFT) and the University of Manchester to Vitalograph Ltd and Vitalograph Ireland. MFT receives royalties which may be shared with the clinical division in which JAS works.
Figures
![Fig. 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/10896934/bin/408_2023_666_Fig1_HTML.gif)
![Fig. 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/10896934/bin/408_2023_666_Fig2_HTML.gif)
![Fig. 3](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/10896934/bin/408_2023_666_Fig3_HTML.gif)
Similar articles
-
Gefapixant for Refractory or Unexplained Chronic Cough?JAMA. 2023 Oct 10;330(14):1335-1336. doi: 10.1001/jama.2023.18508. JAMA. 2023. PMID: 37694857 No abstract available.
-
ATP, an attractive target for the treatment of refractory chronic cough.Purinergic Signal. 2022 Sep;18(3):289-305. doi: 10.1007/s11302-022-09877-z. Epub 2022 Jun 21. Purinergic Signal. 2022. PMID: 35727480 Free PMC article. Review.
-
P2X3-Receptor Antagonists as Potential Antitussives: Summary of Current Clinical Trials in Chronic Cough.Lung. 2020 Aug;198(4):609-616. doi: 10.1007/s00408-020-00377-8. Epub 2020 Jul 13. Lung. 2020. PMID: 32661659 Review.
-
Pharmacotherapeutic Options for Chronic Refractory Cough.Expert Opin Pharmacother. 2020 Aug;21(11):1345-1358. doi: 10.1080/14656566.2020.1751816. Epub 2020 Apr 17. Expert Opin Pharmacother. 2020. PMID: 32301356 Review.
-
Cough in idiopathic pulmonary fibrosis.Eur Respir Rev. 2016 Sep;25(141):278-86. doi: 10.1183/16000617.0090-2015. Eur Respir Rev. 2016. PMID: 27581827 Free PMC article. Review.
Cited by
-
LUNG Year in Review: 2023.Lung. 2024 Feb;202(1):1-4. doi: 10.1007/s00408-024-00671-9. Epub 2024 Feb 2. Lung. 2024. PMID: 38305892 No abstract available.
References
-
- Song WJ, Chang YS, Faruqi S, Kim JY, Kang MG, Kim S, et al. The global epidemiology of chronic cough in adults: a systematic review and meta-analysis. Eur Respir J. 2015;45(5):1479–81. - PubMed
-
- Colak Y, Nordestgaard BG, Laursen LC, Afzal S, Lange P, Dahl M. Risk factors for chronic cough among 14,669 individuals from the general population. Chest. 2017;152(3):563–73. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical